The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“Child-Turcotte’s classification as modified by Pugh has been used extensively in clinical practice to categorize patients according to the severity of liver function impairment [105].”
MethodGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 2×
“The GFR can be precisely measured using the filtrationmarkers inulin, I-iothalamate, Cr-ethylenediaminetetraacetic acid, Tc-diethylenetriaminepentaacetic acid, and iohexol [4, 5, 7].”
BackgroundMethodMartindale: the complete drug reference
(2005) · Choice Reviews Online · doi:10.5860/choice.42-6228 · Cited by 2,688
Model for end-stage liver disease (MELD) and allocation of donor livers
Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., Kremers, W., Lake, J., Howard, T., Merion, R. M., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50016 · Cited by 2,528
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Applied pharmacokinetics : principles of therapeutic drug monitoring
Evans, W. E., Schentag, J. J., & Jusko, W. J. (1992) · Medical Entomology and Zoology · Cited by 1,044
Koepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772
Cystatin C as a marker of GFR—history, indications, and future research
Filler, G., Bökenkamp, A., Hofmann, W., Le Bricon, T., Martínez-Brú, C., & Grubb, A. (2005) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.09.025 · Cited by 734
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652
Self-citationClearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649
Replacement of Renal Function by Dialysis: A textbook of dialysis
(1989) · Springer eBooks · doi:10.1007/978-94-009-1087-4 · Cited by 610
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
First-Pass Elimination: Basic Concepts and Clinical Consequences
Pond, S. M., & Tozer, T. N. (1984) · Clinical Pharmacokinetics · doi:10.2165/00003088-198409010-00001 · Cited by 450
Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism
Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 449
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Bostom, A. G., Kronenberg, F., & Ritz, E. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000022011.35035.f3 · Cited by 410
Mechanisms of bile formation, hepatic uptake, and biliary excretion.
Klaassen, C. D., & Watkins, J. B. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06642-6 · Cited by 390
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†
Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375
Zollner, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22646 · Cited by 362
Drug glucuronidation in humans
Miners, J. O., & Mackenzie, P. I. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90065-t · Cited by 361
Morphine-6-glucuronide, a potent mu agonist
Pasternak, G. W., Bodnar, R. J., Clark, J. A., & Inturrisi, C. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90431-0 · Cited by 361
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-502_4 · Cited by 360
Clearance approaches in pharmacology.
Wilkinson, G. R. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06653-0 · Cited by 355
Morphine intoxication in renal failure: the role of morphine-6-glucuronide.
Osborne, R. J., Joel, S. P., & Slevin, M. L. (1986) · BMJ · doi:10.1136/bmj.292.6535.1548 · Cited by 351
Limitations of Serum Creatinine Level and Creatinine Clearance as Filtration Markers in Cirrhosis
Caregaro, L. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.2.201 · Cited by 331
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
ROSSAT, J., MAILLARD, M., NUSSBERGER, J., BRUNNER, H., & BURNIER, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70056-1 · Cited by 318
Pharmacokinetics of Opioids in Liver Disease
Tegeder, I., L??tsch, J., & Geisslinger, G. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937010-00002 · Cited by 306
Cholongitas, E., Marelli, L., Shusang, V., Senzolo, M., Rolles, K., Patch, D., & Burroughs, A. K. (2006) · Liver Transplantation · doi:10.1002/lt.20824 · Cited by 302
Effects of renal failure on drug transport and metabolism
Sun, H., Frassetto, L., & Benet, L. Z. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.010 · Cited by 290
Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport
Nolin, T., Naud, J., Leblond, F., & Pichette, V (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.59 · Cited by 276
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H.-U., Zatloukal, K., Denk, H., & Trauner, M. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00096-5 · Cited by 275
How to estimate GFR-serum creatinine, serum cystatin C or equations?
Herget-Rosenthal, S., Bökenkamp, A., & Hofmann, W. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.10.014 · Cited by 268
The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
Protein Binding and Kinetics of Drugs in Liver Diseases
Blaschke, T. F. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702010-00003 · Cited by 264
Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Nezasa, K.-I., Tallman, M. N., & Brouwer, K. L. R. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.007 · Cited by 256
Dose Adjustment in Patients with Liver Disease
Delc??, F., Tchambaz, L., Schlienger, R., Drewe, J., & Kr??henb??hl, S. (2005) · Drug Safety · doi:10.2165/00002018-200528060-00005 · Cited by 256
Significance of the Minor Cytochrome P450 3A Isoforms
Daly, A. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645010-00002 · Cited by 254
Effects of aging and liver disease on disposition of lorazepam
Kraus, J. W., Desmond, P. V., Marshall, J. P., Johnson, R. F., Schenker, S., & Wilkinson, G. R. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978244411 · Cited by 252
Liver disease selectively modulates cytochrome P450–mediated metabolism
FRYE, R., ZGHEIB, N., MATZKE, G., CHAVESGNECCO, D., RABINOVITZ, M., SHAIKH, O., & BRANCH, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.006 · Cited by 250
Fuhr, U., Jetter, A., & Kirchheiner, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100050 · Cited by 245
BMA (2003) · Cited by 245
Normal Disposition of Oxazepam in Acute Viral Hepatitis and Cirrhosis
SHULL, H. J., WILKINSON, G. R., JOHNSON, R., & SCHENKER, S. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-4-420 · Cited by 237
Effects of Liver Disease on Pharmacokinetics: An Update
Rodighiero, V. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937050-00004 · Cited by 235
Acyl glucuronide reactivity in perspective: biological consequences
Bailey, M. J., & Dickinson, R. G. (2003) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(03)00020-6 · Cited by 232
George, J., Murray, M., Byth, K., & Farrell, G. C. (1995) · Hepatology · doi:10.1002/hep.1840210121 · Cited by 227
Transporters and Renal Drug Elimination
Lee, W., & Kim, R. B. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121856 · Cited by 222
Furosemide (Frusemide): A Pharmacokinetic/Pharmacodynamic Review (Part II)
Boles Ponto, L. L., & Schoenwald, R. D. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018060-00003 · Cited by 217
Cytochrome P450 and Liver Diseases
Villeneuve, J.-P., & Pichette, V. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335531 · Cited by 215
Downregulation of Hepatic Cytochrome P450 in Chronic Renal Failure
LEBLOND, F., GUÉVIN, C., DEMERS, C., PELLERIN, I., GASCON-BARRÉ, M., & PICHETTE, V. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v122326 · Cited by 213
Morgan, D. J., & McLean, A. J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529050-00005 · Cited by 210
The pharmacokinetics of morphine and morphine glucuronides in kidney failure
Osborne, R., Joel, S., Grebenik, K., Trew, D., & Slevin, M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.127 · Cited by 208
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.
Hasselstrom, J., Eriksson, S., Persson, A., Rane, A., Svensson, J., & Sawe, J. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03638.x · Cited by 205
Applied pharmacokinetics & pharmacodynamics : principles of therapeutic drug monitoring
Burton, M. (2006) · Lippincott Williams & Wilkins eBooks · Cited by 203
Uremic Bleeding: Closing the Circle After 30 Years of Controversies?
Noris, M., & Remuzzi, G. (1999) · Blood · doi:10.1182/blood.v94.8.2569.420k13_2569_2574 · Cited by 202
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Peck, C. C., Barr, W. H., Benet, L. Z., Collins, J., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T., Rodman, J. H., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.47 · Cited by 191
Letter: Thoracic-duct cannulation for bleeding oesophageal varices.
Aderka, D. (1976) · PubMed · Cited by 191
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Pharmacokinetics of Opioids in Renal Dysfunction
Davies, G., Kingswood, C., & Street, M. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631060-00002 · Cited by 181
Clinical Pharmacokinetics: Concepts and applications.
Bryson, S. M. (1983) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1983.tb00901.x · Cited by 177
Engel, G., Hofmann, U., Heidemann, H., Cosme, J., & Eichelbaum, M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90001-6 · Cited by 176
Caffeine: A Model Compound for Measuring Liver Function
Renner, E., Wietholtz, H., Huguenin, P., Arnaud, M. J., & Preisig, R. (1984) · Hepatology · doi:10.1002/hep.1840040107 · Cited by 171
Le Couteur, D. G., Fraser, R., Hilmer, S., Rivory, L. P., & McLean, A. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00004 · Cited by 166
Zhang, Y., Zhang, L., Abraham, S., Apparaju, S., Wu, T.-C., Strong, J., Xiao, S., Atkinson Jr, A., Thummel, K., Leeder, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.208 · Cited by 164
Principles of Drug Administration in Renal Insufficiency
Lam, Y. W. F., Banerji, S., Hatfield, C., & Talbert, R. L. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732010-00002 · Cited by 160
Orlando, R., Mussap, M., Plebani, M., Piccoli, P., De Martin, S., Floreani, M., Padrini, R., & Palatini, P. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.6.850 · Cited by 159
UDP Glucuronosyltransferase mRNA Levels in Human Liver Disease
Congiu, M. A., Mashford, M. L., Slavin, J., & Desmond, P. V. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.2.129 · Cited by 157
EVIDENCE FOR DOWN-REGULATION OF BETA-2-ADRENOCEPTORS IN CIRRHOTIC PATIENTS WITH SEVERE ASCITES
Gerbes, A., Jüngst, D., Remien, J., Sauerbruch, T., & Paumgartner, G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91556-4 · Cited by 156
Lötsch, J., Zimmermann, M., Darimont, J., Marx, C., Dudziak, R., Skarke, C., & Geißlinger, G. (2002) · Anesthesiology · doi:10.1097/00000542-200210000-00011 · Cited by 155
Assessment of Liver Metabolic Function: Clinical Implications
Brockmöller, J., & Roots, I. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427030-00005 · Cited by 152
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
Mahmood, I., & Green, M. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00001 · Cited by 150 · cited 1×
“After glomerular filtration, peptides can be excreted unchanged in the urine or degraded to products that are excreted in the urine [ 29 ].”
BackgroundMolecular regulation of hepatocellular transport systems in cholestasis
Trauner, M., Meier, P. J., & Boyer, J. L. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80179-2 · Cited by 144
Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain
Hiraoka, H., Yamamoto, K., Miyoshi, S., Morita, T., Nakamura, K., 門井雄司, Kunimoto, F., & Horiuchi, R. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02393.x · Cited by 140
The Effect of Liver Cirrhosis on the Regulation and Expression of Drug Metabolizing Enzymes
Elbekai, R. H., Korashy, H. M., & El‐Kadi, A. O. S. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489054 · Cited by 139
Ponto, L. L. B., & Schoenwald, R. D. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018050-00004 · Cited by 139
Bakti, G., Fisch, H. U., Karlaganis, G., Minder, C. E., & Bircher, J. (1987) · Hepatology · doi:10.1002/hep.1840070403 · Cited by 137
Kinirons, M. T., O’Shea, D., Kim, R. B., Groopman, J. D., Thummel, K. E., Wood, A. J. J., & Wilkinson, G. R. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70029-9 · Cited by 134
Enhanced Bioavailability and Decreased Clearance of Analgesics in Patients with Cirrhosis
Neal, E. A., Meffin, P. J., Gregory, P. B., et al. (1979) · Gastroenterology · doi:10.1016/s0016-5085(79)80017-7 · Cited by 133
EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
Sun, H. L., Huang, Y., Frassetto, L. A., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000521 · Cited by 128
Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats
Naud, J., Michaud, J., Boisvert, C., Desbiens, K., Leblond, F. A., Mitchell, A., Jones, C., Bonnardeaux, A., & Pichette, V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112631 · Cited by 126
Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic Activity
Nolin, T. D., Appiah, K. K., Kendrick, S. A., Le, P. T., McMonagle, E., & Himmelfarb, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060610 · Cited by 126
Early Development of Therapeutic Biologics - Pharmacokinetics
Baumann, A. (2005) · Current Drug Metabolism · doi:10.2174/138920006774832604 · Cited by 125
Bourasset, F., Cisternino, S., Temsamani, J., & Scherrmann, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01990.x · Cited by 125
McGurk, K. A., Brierley, C. H., & Burchell, B. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00534-0 · Cited by 123
Orlando, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.007 · Cited by 123
Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease
Dowling, T. C., Briglia, A., Fink, J. C., Hanes, D. S., Light, P. D., Stackiewicz, L., Karyekar, C. S., Eddington, N. D., Weir, M. R., & Henrich, W. L. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00056-0 · Cited by 122
Mechanisms of renal anionic drug transport
El‐Sheikh, A. A. K., Masereeuw, R., & Rüssel, F. G. M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.085 · Cited by 120
Proulx, N. L., Akbari, A., Garg, A. X., Rostom, A., Jaffey, J., & Clark, H. D. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh839 · Cited by 119
Vidal, L., Shavit, M., Fraser, A., Paul, M., & Leibovici, L. (2005) · BMJ · doi:10.1136/bmj.38476.471088.3a · Cited by 118
The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil
Muirhead, G. J., Wilner, K. D., Colburn, W. A., Haug‐Pihale, G., & Rouviex, B. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.00029.x · Cited by 118
Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators
Guévin, C., Michaud, J., Naud, J., Leblond, F. A., & Pichette, V. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704951 · Cited by 114
Breath testing for human liver function assessment
Armuzzi, A., Candelli, M., Zocco, M. A., Andréoli, A., LORENZO, A. D., Nista, E. C., Miele, L., Cremonini, F., Cazzato, I. A., Grieco, A., et al. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01374.x · Cited by 113
Pharmacogenetics of Oral Anticoagulants
Stehle, S., Kirchheiner, J., Lazar, A., & Fuhr, U. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847090-00002 · Cited by 113
Concepts basic to pharmacokinetics
Tozer, T. N. (1981) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(81)90077-2 · Cited by 111
Pharmacokinetic study of memantine in healthy and renally impaired subjects
Periclou, A. P., Ventura, D., RAO, N., & Abramowitz, W. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.005 · Cited by 108
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450
Michaud, J., Dubé, P., Naud, J., Leblond, F. A., Desbiens, K., Bonnardeaux, A., & Pichette, V. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706138 · Cited by 108
Decreased in Vivo Metabolism of Drugs in Chronic Renal Failure
Leblond, F. A., Giroux, L., Villeneuve, J., & Pichette, V. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15079-9 · Cited by 108
Kleinbloesem, C. H., van Harten, J., Wilson, J. P. H., et al. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.134 · Cited by 108
Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy
Tozer, T. N., & Rowland, M. (2006) · Cited by 107
George, J., Liddle, C., Murray, M. T., Byth, K., & Farrell, G. C. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00515-n · Cited by 103
Downregulation of Intestinal Cytochrome P450 in Chronic Renal Failure
Leblond, F. A., Petrucci, M., Dubé, P., Bernier, G., Bonnardeaux, A., & Pichette, V. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000017575.50319.77 · Cited by 103
Steady-State Extrarenal Sorbitol Clearance as a Measure of Hepatic Plasma Flow
Zeeh, J., Lange, H., Bosch, J., Pohl, S., Lösgen, H., Eggers, R., Navasa, M., Jaime Chesta, R., & Bircher, J. (1988) · Gastroenterology · doi:10.1016/s0016-5085(88)80024-6 · Cited by 102
Chalasani, N., Gorski, J. C., Patel, N. H., Hall, S. D., & Galinsky, R. E. (2001) · Hepatology · doi:10.1053/jhep.2001.29306 · Cited by 100
Adedoyin, A. B., Arns, P. A., Richards, W. O., Wilkinson, G. R., & Branch, R. A. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90017-0 · Cited by 97
Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment
Kovarik, J. M., Sabia, H. D., Figueiredo, J., Zimmermann, H., Reynolds, C., Dilzer, S. C., Lasseter, K. C., & Rordorf, C. M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)15633-x · Cited by 97
Plasma Disappearance Rate of Indocyanine Green in Liver Dysfunction
Faybik, P., & Hetz, H. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.01.049 · Cited by 95
Application of newer clearance techniques for the determination of glomerular filtration rate
Gaspari, F., Perico, N., & Remuzzi, G. (1998) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199811000-00009 · Cited by 93
THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING
Liu, L., & Pang, K. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001149 · Cited by 93
Prognostic value of the aminopyrine breath test in cirrhotic patients
Villeneuve, J., Infante‐Rivard, C., Ampelas, M., Pomier–Layrargues, G., Huet, M. P., & Marleau, D. (1986) · Hepatology · doi:10.1002/hep.1840060520 · Cited by 92
Mdr1 Limits CYP3A Metabolism in Vivo
Lan, L.-B., Dalton, J. T., & Schuetz, E. G. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.4.863 · Cited by 90
Individual Variation in First-Pass Metabolism
Tam, Y. K. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325040-00005 · Cited by 87
Principles and Clinical Application of Assessing Alterations in Renal Elimination Pathways
Tett, S. E., Kirkpatrick, C. M. J., Gross, A. S., & McLachlan, A. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342140-00002 · Cited by 87
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin
Kays, M. B., Overholser, B. R., Mueller, B. A., Moe, S. M., & Sowinski, K. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.08.027 · Cited by 86
Decreased first-pass metabolism of labetalol in chronic liver disease.
Homeida, M. M. A., Jackson, L., & Roberts, C. J. (1978) · BMJ · doi:10.1136/bmj.2.6144.1048 · Cited by 79
Zuckerman, M. J., Menzies, I. S., Ho, H., Gregory, G. G., Casner, N. A., Crane, R., & Hernandez, J. A. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000026307.56909.21 · Cited by 79
Lam, J. L., Okochi, H., Huang, Y., & Benet, L. Z. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009258 · Cited by 79
Extrahepatic metabolism of morphine occurs in humans
Mazoit, J., Sandouk, P., Scherrmann, J., & Roche, A. J. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.203 · Cited by 78
Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease
Klotz, U. E., Antonin, K. H., Brügel, H. G., et al. (1977) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1977214430 · Cited by 77
Kurnik, D., Wood, A., & Wilkinson, G. R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.002 · Cited by 76
Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis
Regårdh, C. G., Jordö, L., Ervik, M., Lundborg, P. G., Olsson, R., & Rönn, O. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106050-00004 · Cited by 73
Role of Parathyroid Hormone in the Downregulation of Liver Cytochrome P450 in Chronic Renal Failure
Michaud, J., Naud, J., Chouinard, J. C. A., Désy, F., Leblond, F. A., Desbiens, K., Bonnardeaux, A., & Pichette, V. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010035 · Cited by 72
Gastrointestinal dysfunction in liver disease and portal hypertension
Quiqley, E. M. M. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282341 · Cited by 70
Glucuronidation of Drugs by Hepatic Microsomes Derived from Healthy and Cirrhotic Human Livers
Furlan, V., Demirdjian, S., Bourdon, O., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38249-7 · Cited by 69
The Erythromycin Breath Test For the Prediction of Drug Clearance
Rivory, L. P., Slaviero, K. A., Hoskins, J. M., & Clarke, S. J. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00001 · Cited by 68
The Role of the Sinusoidal Endothelium in Liver Function
Reichen, J. (1999) · Physiology · doi:10.1152/physiologyonline.1999.14.3.117 · Cited by 64
Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient
GIBSON, T. P., Giacomini, K. M., Briggs, W. A., et al. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.94 · Cited by 64
Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis
Kawasaki, S., Imamura, H., Bandai, Y., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90775-t · Cited by 63
Antiarrhythmics: Elimination and Dosage Considerations in Hepatic Impairment
Klotz, U. E. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746120-00002 · Cited by 62
Hepatic clearance and liver blood flow
Keiding, S. (1987) · Journal of Hepatology · doi:10.1016/s0168-8278(87)80552-4 · Cited by 61
Diagnosis and Management of Chronic Kidney Disease
Graves, J. W. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1064 · Cited by 61
Peck, C. C., Barr, W. H., Benet, L. Z., Collins, J. M., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T. M., Rodman, J. H., et al. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810630 · Cited by 61
Toublanc, N., Sargentini‐Maier, M. L., Lacroix, B. D., Jacqmin, P., & Stockis, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00004 · Cited by 60
Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.
Soons, P. A., & Breimer, D. D. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05606.x · Cited by 58
Cholestasis and Endogenous Opioids: Liver Disease and Exogenous Opioid Pharmacokinetics
Davis, M. P. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746100-00002 · Cited by 56
Kullak-Ublick, G. A., Baretton, G. B., Oswald, M., Renner, E. L., Paumgartner, G., & Beuers, U. (2002) · Hepatology Research · doi:10.1016/s1386-6346(01)00159-0 · Cited by 55
Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results
Frassetto, L. A., Poon, S., Tsourounis, C., Valera, C., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100148 · Cited by 53
Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization??in Clinical Oncology
Zandvliet, A. S., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847080-00001 · Cited by 47
Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin
How, P., Fischer, J. H., Arruda, J. A. L., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580407 · Cited by 47
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver
Pentik�inen, P. J., Neuvonen, P. J., & Jostell, K. ‐. (1980) · European Journal of Clinical Pharmacology · doi:10.1007/bf00625801 · Cited by 45
Contribution of the Human Kidney to the Metabolic Clearance of Drugs
Vree, T. B., Hekster, Y. A., & Anderson, P. G. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202601116 · Cited by 45
Tzeng, T., Schneck, D. W., Birmingham, B. K., Mitchell, P., Zhang, H., Martin, P. D., & Kung, L.-P. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802312807 · Cited by 40
Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.
Soons, P. A., de Boer, A., Cohen, A., & Breimer, D. D. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03976.x · Cited by 38
Bricker, N. S., Morrin, P. A. F., & Kime, S. W. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v891470 · Cited by 37
Hippurate participates in the correction of metabolic acidosis
Dzurik, R., Spustová, V., Krivošíková, Z., & Gazdíková, K. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.59780278.x · Cited by 37
Off‐label and unlicensed prescribing for children: have we made any progress?
Waller, D. G. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02987.x · Cited by 37
Dynamic tests to study liver function.
Burra, P., & Masier, A. (2004) · PubMed · Cited by 37
EFFECT OF CHRONIC RENAL INSUFFICIENCY ON HEPATIC AND RENAL UDP-GLUCURONYLTRANSFERASES IN RATS
Yu, C., Ritter, J. K., Krieg, R. J., Rege, B., Karnes, T. H., & Sarkar, M. A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006601 · Cited by 35
Molino, G., Avagnina, P., Belforte, G., & Bircher, J. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90139-1 · Cited by 30
Gross, A. S., McLachlan, A. J., Minns, I., Beal, J. L., & Tett, S. E. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01390.x · Cited by 28
Aarons, L. J., Balant, L. P., Mentré, F., Morselli, P. L., Rowland, M., Steimer, J., & Vožeh, S. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00191898 · Cited by 28
Fabre, D., Bressolle, F., Goméni, R., Bouvet, O., Dubois, A., Raffanel, C., Gris, J., & Galtier, M. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324040-00006 · Cited by 27
Dose Adaptation of Antineoplastic Drugs in Patients with Liver Disease
Tchambaz, L., Schlatter, C., Jakob, M., hl-Melcher, A. K. H., Wolf, P. S., & hl, S. K. H. (2006) · Drug Safety · doi:10.2165/00002018-200629060-00004 · Cited by 26
Niwa, T., Miyazaki, T., Katsuzaki, T., Tatemichi, N., & Takei, Y. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000189456 · Cited by 23
Drug Dosing Considerations in Alternative Hemodialysis
Decker, B. S., Mueller, B. A., & Sowinski, K. M. (2007) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2007.03.004 · Cited by 22
Hildebrand, M. S., Hellstern, A., Humpel, M., Hellenbrecht, D., & Saller, R. (1990) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190123 · Cited by 19
Regulatory Aspects of Pharmacokinetic Profiling in Special Populations: A European Perspective
Edholm, M., Berglund, E. G., & Salmonson, T. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847110-00001 · Cited by 16
Drug Acetylation in Liver Disease
Levy, M., Caraco, Y., & Geißlinger, G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834030-00004 · Cited by 13
Drug Dosage in Dialysis Patients
Golper, T. A., Marx, M. A., Shuler, C. L., & Bennett, W. M. (2008) · Springer eBooks · doi:10.1007/978-0-585-36947-1_30 · Cited by 9
Cited by
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“For renal-impaired patients, dose adjustment may be needed for peptide drugs to avoid accumulation and higher drug exposure, as inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy (99,100).”
BackgroundMatzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.322 · Cited by 462
Blot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Metadata
- Authors
- Verbeeck, R. K., & Musuamba, F. T.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2009-06-20
- Volume
- 65
- Issue
- 8
- Pages
- 757-773
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2133948398
- Cited by
- 717
- References
- 167
- FWCI
- 24.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.